Drug · CHEMBL773
GLYCINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. GLYCINE. Drugs and targets, record CHEMBL773. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL773
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases9
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| schizophrenia | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0005090 |
| malnutrition | Approval | TTD | 3 | 2 | https://conductscience.org/library/drugs?q=EFO_0008572 |
| Cognitive impairment | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=HP_0100543 |
| alcohol dependence | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0007079 |
| schizoaffective disorder | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005487 |
| Addictive alcohol use | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0030955 |
| cognitive disorder | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002039 |
| obsessive-compulsive disorder | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0008114 |
| psychotic disorder | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005485 |
Source Open Targets
Trials14
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 5 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00635102 | Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects | 57 | 2016-12-16 | glycine | Its name | ClinicalTrials.gov | |
| NCT00338598 | Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism | Phase 2 | 20 | 2017-04-12 | glycine | Its name | ClinicalTrials.gov |
| NCT00291226 | Glycine vs Placebo for the Schizophrenia Prodrome | Phase 2/3 | 8 | 2016-12-29 | glycine | Its name | ClinicalTrials.gov |
| NCT01720316 | Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders | Phase 2 | 2 | 2017-04-18 | glycine | Its name | ClinicalTrials.gov |
| NCT00222235 | Adjunctive Treatment for Decreasing Symptoms of Schizophrenia | Phase 2/3 | 240 | glycine | Its name | ClinicalTrials.gov | |
| NCT04738422 | Determining Airway pH by Compartmental Exhaled Nitric Oxide Levels During Alkaline Buffer Challenge | Phase 2 | 150 | glycine | Its name | ClinicalTrials.gov | |
| NCT00133562 | HIAS II - Study of Nutritional Supplementation in Hospitalized Children With Persistent Diarrhea or Malnutrition | Phase 3 | 108 | glycine | Its name | ClinicalTrials.gov | |
| NCT00338221 | Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition | Phase 3 | 108 | glycine | Its name | ClinicalTrials.gov | |
| NCT03166228 | Hemodynamic Changes During Operative Hysteroscopy | Phase 2 | 60 | glycine | Its name | ClinicalTrials.gov | |
| NCT00405535 | Adjunctive Glycine for Obsessive Compulsive Disorder | 24 | glycine | Its name | ClinicalTrials.gov |
1 to 10 of 14
See all 14 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Alcoholic Subjects vs Healthy Subjects: serious adverse events | 0 of 27 | 0 of 30 | 57 | NCT00635102 | Trial comparisons |
| Glycine vs Placebo: deaths from any cause | 0 of 10 | 0 of 10 | 20 | NCT00338598 | Trial comparisons |
| Glycine vs Placebo: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT00338598 | Trial comparisons |
| Glycine vs Placebo Group: serious adverse events | 0 of 4 | 0 of 4 | 8 | NCT00291226 | Trial comparisons |
| Glycine vs Placebo: deaths from any cause | 0 of 2 | 0 of 2 | 4 | NCT01720316 | Trial comparisons |
| Glycine vs Placebo: serious adverse events | 0 of 2 | 0 of 2 | 4 | NCT01720316 | Trial comparisons |
Papers from its trials7
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Verbal Learning | 2 | 1 | ConductCognition |
| Continuous Performance Test | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL773
GET https://conductscience.org/api/drugs/v1/CHEMBL773/targets